Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
P/B ratio for Roivant Sciences Ltd. (ROIV)
P/B ratio as of 2024: 1.37
According to Roivant Sciences Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.37. At the end of 2023 the company had a P/B ratio of 3.27.
P/B ratio history for Roivant Sciences Ltd. from 2019 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 1.37 |
| 2023 | 3.27 |
| 2022 | 1.62 |
| 2021 | 1.21 |
| 2020 | 1.10 |
| 2019 | 3.12 |